Codeine

Overview

Codeine is an opioid medication used in veterinary medicine primarily for cough suppression and mild analgesia in dogs and cats. It belongs to the phenanthrene class of opioid agonists and acts mainly on mu-opioid receptors in the central nervous system.

In small animal practice, codeine may be used as an antitussive to control persistent cough or as a mild analgesic. However, its effectiveness—especially for pain control—can vary between species due to differences in metabolism. In dogs, oral bioavailability is very low because of extensive first-pass hepatic metabolism, which may limit its analgesic effect.

Mechanism of Action (MOA): Codeine exerts its effects primarily through activation of central mu-opioid receptors. This leads to suppression of the cough reflex in the medullary cough center, analgesia through modulation of pain pathways in the central nervous system, and decreased gastrointestinal motility. The drug is metabolized in the liver to several metabolites, including compounds with opioid activity.

Indications

Codeine is used in dogs and cats primarily for its opioid effects, including cough suppression and mild analgesia. In some cases, it may also be used for gastrointestinal indications due to its effects on intestinal motility.

• Cough suppression (antitussive): Used to reduce persistent or nonproductive cough by suppressing the cough center in the brain.
• Analgesia: May be used for mild to moderate pain management in dogs and cats, although analgesic efficacy may vary between species.

Dosage (Reference)

Dog

In dogs, codeine is mainly used as an antitussive or mild analgesic. Because oral bioavailability is very low in dogs due to extensive first-pass metabolism, clinical response may vary between patients.

Cat

In cats, codeine may be used for analgesia, but patients should be monitored closely because opioids can sometimes cause central nervous system stimulation instead of sedation.

Warnings & Precautions

Codeine is an opioid medication and should be used cautiously in dogs and cats due to its effects on the respiratory, gastrointestinal, and central nervous systems. Careful patient selection and monitoring are recommended.

• Hypersensitivity: Codeine is contraindicated in animals with known hypersensitivity to codeine or other opioid analgesics.
• Respiratory depression: Do not use in patients with significant respiratory depression or severe respiratory disease, as opioids may further reduce respiratory drive.
• Gastrointestinal obstruction: Contraindicated in patients with known or suspected gastrointestinal obstruction.
• Toxin-induced diarrhea: Should not be used for diarrhea caused by toxin ingestion until the toxin has been eliminated from the gastrointestinal tract.
• Monoamine oxidase inhibitors (MAOIs): Codeine should not be used in animals currently receiving MAO inhibitors or within 14 days of their discontinuation.
• Endocrine and systemic disease: Use cautiously in animals with hypothyroidism, severe renal insufficiency, hypoadrenocorticism (Addison disease), or in geriatric or debilitated patients.
• Neurologic conditions: Use with caution in patients with head trauma, increased intracranial pressure, seizure disorders, or acute abdominal disease because opioids may mask clinical signs.
• Respiratory compromise: Use extreme caution in animals with pulmonary disease or acute respiratory dysfunction.
• Withdrawal risk: Abrupt discontinuation after long-term therapy may cause withdrawal signs; gradual dose reduction is recommended.
• Combination products: Products containing acetaminophen should not be used in cats or ferrets due to toxicity risk.

Drug Interactions

Codeine may interact with several medications that affect central nervous system function,
hepatic metabolism, or gastrointestinal motility. When used with other drugs, monitoring for
excessive sedation, respiratory depression, or altered therapeutic response is recommended.

• Anticholinergic drugs (e.g., atropine, glycopyrrolate, oxybutynin):
  Concurrent use may increase the risk of constipation due to additive effects on gastrointestinal motility.
• Azole antifungals (e.g., itraconazole, ketoconazole):
  May increase systemic exposure to codeine and enhance conversion to morphine.
• Cannabidiol (CBD):
  May potentiate CNS depression when administered with opioids.
• Clopidogrel:
  Opioids may delay gastrointestinal absorption and reduce formation of the active clopidogrel metabolite, decreasing its antiplatelet effect.
• Other CNS depressants (e.g., anesthetics, antihistamines, barbiturates, benzodiazepines, muscle relaxants, phenothiazines):
  Concurrent use may increase the risk of excessive sedation or respiratory depression.
• Desmopressin (DDAVP):
  May increase the risk of hyponatremia when used with opioids.
• Dexamethasone:
  May reduce codeine exposure and decrease formation of its active metabolites.
• Diuretics (e.g., furosemide, hydrochlorothiazide):
  Opioids may decrease the effectiveness of diuretics by promoting antidiuretic hormone release.
• Macrolide antibiotics (e.g., clarithromycin, erythromycin):
  May increase codeine exposure and enhance formation of morphine.
• Monoamine oxidase inhibitors (MAOIs) (e.g., amitraz, selegiline, linezolid):
  Concurrent use or use within 14 days is contraindicated due to increased risk of severe CNS effects.
• Prokinetic agents (e.g., metoclopramide, cisapride):
  Opioids may reduce the effectiveness of gastrointestinal prokinetic medications.
• Quinidine:
  May increase systemic exposure to codeine and its active metabolites.
• Serotonergic drugs (e.g., mirtazapine, trazodone):
  Concurrent use may increase the risk of serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, paroxetine, sertraline):
  May increase codeine exposure and increase the risk of serotonin syndrome.
• Terbinafine:
  May increase codeine exposure and formation of morphine metabolites.
• Tricyclic antidepressants (e.g., amitriptyline, clomipramine):
  Concurrent use may increase the risk of serotonin syndrome.
• Naloxone:
  Antagonizes opioid effects and is used clinically to reverse opioid-induced respiratory depression.

Side Effects & Overdose

Side Effects

Codeine is generally well tolerated in dogs and cats, but typical opioid-related adverse effects may occur, particularly with higher doses or prolonged use.

• Sedation: The most commonly observed effect, resulting in drowsiness or decreased activity.
• Gastrointestinal effects: May include anorexia, vomiting, constipation, ileus, and spasms of the biliary or pancreatic ducts.
• Respiratory depression: Usually uncommon at normal doses but may occur with high doses or in susceptible patients.
• CNS stimulation in cats: Cats may develop hyperexcitability, tremors, or seizures instead of sedation.

Overdose

Opioid overdose can produce significant central nervous system and respiratory depression. Prompt recognition and supportive treatment are essential.

• Common signs: Severe sedation, respiratory depression, hypothermia, muscle weakness, or cardiovascular collapse.
• Airway management: Maintaining adequate ventilation is critical in severe overdose cases.
• Gastrointestinal decontamination: If ingestion occurred recently, standard decontamination protocols may be considered.
• Reversal agent: Naloxone may be administered to reverse opioid-induced respiratory or CNS depression.
• Supportive care: In severe cases, repeated naloxone dosing and mechanical respiratory support may be required.

Key Notes

Practical clinical points that can help guide the safe and effective use of codeine in dogs and cats:

• Species variability: The clinical effectiveness of codeine varies between species due to differences in hepatic metabolism and metabolite formation.
• Low oral bioavailability in dogs: Extensive first-pass metabolism limits systemic availability after oral administration, which may reduce analgesic effectiveness.
• Active metabolites: Codeine is metabolized primarily to codeine-6-glucuronide, which possesses opioid activity.
• Onset and duration: In humans, onset typically occurs within about 30 minutes with analgesic effects lasting 4–6 hours; similar timing is generally expected clinically in veterinary patients.
• Controlled drug status: Codeine is a regulated opioid medication, and storage, prescribing, and dispensing must comply with controlled-substance regulations.